Xeris Biopharma Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
XERS$15.83-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Index to Financial Statements | |||
|---|---|---|---|
| Page | |||
| Management’s Report on Internal Control Over Financial Reporting | 75 | ||
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 76 | ||
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 185) | 78 | ||
| Financial Statements | |||
| Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022 | 79 | ||
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | 80 | ||
| Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2023, 2022 and 2021 | 81 | ||
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | 82 | ||
| Notes to Consolidated Financial Statements | 84 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.